2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
New data supporting neurotrophic factor as a potential treatment for Parkinson’s
An article in the Journal of the International Movement Disorders Society reports on some pre-clinical (laboratory) data supporting the development of ‘Glial cell line-Derived Neurotrophic Factor’ (GDNF) as a potential disease-modifying treatment for Parkinson’s.
The 2023 International Linked Clinical Trials meeting
In June, Cure Parkinson’s gathered 23 of the world’s leading Parkinson’s experts together for the annual International Linked Clinical Trials (iLCT) meeting. The iLCT committee was created in 2012 through a collaboration between Cure Parkinson’s and Van Andel Institute with the goal of prioritising potential…
Positive phase 1 results for BlueRock
BlueRock Therapeutics has reported positive results from the phase 1 trial of its cell-replacement therapy for Parkinson’s
Parkinson’s drug therapies in the clinical trial pipeline: 2023 update
Cure Parkinson’s has collaborated annually with Parkinson’s advocates and the Michael J Fox Foundation to present an update on the clinical trials landscape for Parkinson’s. The 2023 report is now published.
Phase 2 UDCA in Parkinson’s trial results published
Cure Parkinson’s is excited to announce that the results from the ‘UP Study’ – a phase 2 study of the liver drug UDCA in Parkinson’s – will be published in the academic journal Movement Disorders.